Seizures in a boy with subacute sclerosing panencephalitis during high-dose intrathecal interferon-alpha therapy.
A 27-month-old boy was admitted with speech abnormality, inability to walk, and involuntary movements. He was diagnosed with subacute sclerosing panencephalitis based on clinical and laboratory findings. Inosiplex (100 mg/kg/day orally) plus intrathecal interferon-alpha (3 million units/dose twice per week) in a standard regime were given. After four doses of interferon it was prescribed as 6 million units/dose/week because he had been admitted from a remote district. One day after giving the second dose of 6 million units of interferon, two generalized tonic-clonic seizures that occurred within an hour, associated with high fever, which lasted approximately 5 minutes were observed. An antiepileptic agent was not administered because electroencephalogram results did not indicate epileptic discharges. After this condition we returned to the first treatment protocol of interferon (3 million units/dose twice per week). At the current time, he is in the fifth month of follow-up and remains convulsion-free. To the best of our knowledge, seizures as a result of high-dose intrathecal interferon in subacute sclerosing panencephalitis has not been reported in the literature. Our patient demonstrated that it is reasonable to avoid the use of high-dose intrathecal interferon-alpha in childhood.
Caksen
Hüseyin
H
Department of Pediatrics, Yüzüncü Yil University Faculty of Medicine, Van, Turkey.
Odabaş
Dursun
D
Ataş
Bülent
B
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004829:Epilepsy, Generalized / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D007278:Injections, Spinal; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy*
D000970:Antineoplastic Agents; D016898:Interferon-alpha